TABLE 2.
Morusin activity in different cancers.
| Cancer | Targeted pathway | Impact of morusin | References |
|---|---|---|---|
| Hepatocellular carcinoma | STAT3 Pathway | G1 arrest | Cho et al. (2021) |
| Renal cell carcinoma | MAPK Pathway | Lowering ERK levels | Yang et al. (2020) |
| Colorectal cancer | PI3K/Akt Pathway | Inactivation of Akt | Zhou et al. (2021) |
| Nasopharyngeal carcinoma | ERK1/2 Pathway | Suppressing the expression of MMP-2 | Huang et al. (2020) |
| Breast cancer | STAT3 Pathway | Suppressing Survivin and inducing Bax proteins | Kang et al. (2017) |
| Prostate cancer | STAT3 Pathway | Inhibition of phosphorylation of STAT3 | Lim et al. (2015) |
| Gastric cancer | MAPK Pathway | Down-regulating c-Myc and CDKs | Wang et al. (2017) |
| Glioblastoma multiforme | STAT3 Pathway | Downregulation of Bcl-2 and upregulation of Bax | Guo et al. (2016) |
Abbreviations: STAT3, Signal transducers and activators of transcription 3, MAPK, Mitogen-activated protein kinase, Bcl-2, B-cell lymphoma 2, CDK, Cyclin-dependent kinases, C-Myc, Cellular myelocytomatosis, BAX, Bcl-2-associated X protein, MMP, matrix metalloproteinase.